Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,240 total articles
GrafTech makes graphite electrodes and needle coke used in electric arc furnace steelmaking and other industrial processes. With commodity-driven cyclicality priced in, the stock's sub-$8 valuation reflects stress rather than a recovery scenario. We lay out a mid-term (45 trading days) entry at $7.64, stop at $6.00 and a $12.00 target tied to an el…
Alphatec (ATEC) cratered after a May earnings report that flagged installation timing issues and missed EOS unit deliveries. The stock has stabilized and is showing bullish technicals while trading at a cheaper revenue multiple than the 2025 peak. This is a tactical long: enter on a gentle dip, use a tight stop to respect execution risk, and target…
Corebridge Financial is a defensive insurance franchise with a surprisingly attractive capital-return runway. Recent reinsurance transactions, a steady dividend, and management's push toward shareholder distributions are underappreciated by the market. The trade: enter at $34.00, stop $30.00, target $40.00—position trade, horizon ~45–180 trading da…
Paymentus is a cloud-first payments platform with accelerating transaction volume and a strong cash flow profile. At $40.09 the stock trades at a premium but the company’s debt-free balance sheet, positive free cash flow of $159M and recent double-digit to high-double-digit revenue growth create an attractive setup if management deploys capital int…
Centene's recent membership declines look ugly at first glance, but management's shift to prioritize margins, a surprisingly cheap valuation (EV/EBITDA ~5.2, P/FCF ~3.5), and regulatory tailwinds in Medicare create a practical trade: buy on weakness with a tight stop. This is a mid-term swing idea that bets on margin recovery, rate clarity, and imp…
Amazon is showing signs of stronger AWS momentum while the company is entering a heavier investment cycle that will pressure free cash flow near term. The setup favors a mid-term long trade that captures upside from multiple expansion and continued AWS growth, but it requires disciplined risk management against capex- and consumer-retail headwinds.
Nano Labs (NA) trades like a microcap walking back from panic. With a market cap of just $44.3M, a price-to-book under 0.4 and a P/E near 2.0, the stock is priced for disappointment. Recent technical stabilization, CEO insider buying, and a clear pipeline of AI and data-center initiatives suggest the downside is limited and upside is meaningful ove…
Revolution Medicines (RVMD) is a speculative, clinical-stage oncology name that has re-rated sharply in 2026 after Breakthrough Therapy recognition for daraxonrasib and fresh institutional buying. The setup combines a binary regulatory/catalyst path with elevated short interest and a valuation that still reflects pre-revenue status. This trade idea…
Disney just reported a clean Q3 with 7% revenue growth and a significant boost to profitability. With management pushing a $9 billion buyback, free cash flow of roughly $8.3 billion, and forward earnings that analysts peg in the low-teens multiple, the risk/reward supports a measured long into the next content and parks cycle. This idea lays out en…
Nano Labs is trading at $1.83 with a $44.3M market cap, a P/E near 2.0 and PB of 0.40. Recent steps - a Memorandum of Understanding to explore North America AI data centers, a hardware product roll-out and an insider purchase of 480,000 shares - make the pullback a tactical buy. We propose a mid-term swing: enter $1.83, stop $1.55, target $3.50 (45…
RBGLY ($14.36) trades at a market cap of ~$46.3B, a P/E of ~12 and a dividend yield near 3.7%. Litigation tied to Enfamil infant-formula claims has created headline risk, but the underlying Hygiene, Health and Nutrition franchises benefit from steady demand and sector tailwinds. MACD and RSI show bullish technical momentum. This trade idea proposes…
Compugen trades at $2.31 with a $218M market cap, a P/E of 6.4 and a 52-week range of $1.30 to $3.24. Volume and short interest have risen ahead of an upcoming MAIA-related catalyst; the setup offers an asymmetric trade: defined downside with an attractive upside target near the prior high. We favor a mid-term long (45 trading days) with clear entr…
Shoals Technologies (SHLS) sits at the intersection of robust top-line growth and measurable execution risk. Recent quarterly strength and a favorable ITC ruling underpin a constructive thesis; a reset in gross-margin expectations and negative free cash flow compress the multiple today and create a tactical long entry around the current share price…
Nano Labs (NA) trades at a micro-cap valuation with a P/E near 2 and a market cap of roughly $44M. Recent product launches, a North America MOU for AI data centers, and insider buying point to upside. We lay out a tactical long with clear entry, targets, and stop while flagging liquidity and execution risks.
Southern First (SFST) just cleared a critical technical and fundamental hurdle after a better-than-expected quarter and visible margin expansion. With a market cap near $610M, low leverage and improving profitability, the case for a tactical long over the next 45 trading days is compelling — but not free of risks. Entry, stop and target are laid ou…
Satellogic is showing early signs of product-market fit with sovereign customers, improving operating metrics and a rare positive operating cash flow print. The stock looks actionable on a long trade while the market re-rates growth into revenue and government-backed deals. This idea lays out a clear entry, stop and target with a 180 trading-day ho…
Tesla trades near $320 with a market cap above $1.2 trillion and multiples that price in a successful transition from an auto maker to an AI/robotics platform. Near-term fundamentals are under pressure - compressed margins and plunging profitability - but the company still generates meaningful free cash flow and controls assets central to any futur…
Tenable is transitioning from defensive vendor to AI-enabled exposure management leader. Recent product launches (Tenable Hexa AI), FedRAMP High authorization, and channel partnerships are shifting investor perception. Valuation looks stretched on trailing earnings but is reasonable on free cash flow and revenue multiples. A disciplined long trade …
Eli Lilly delivered a robust Q2 with revenue near $23B and hefty profit beats driven by Mounjaro and Zepbound. The market has already priced much of that success - valuation sits near 40x earnings and momentum indicators have cooled. This is an actionable tactical long: enter at current levels, target the 52-week high, and use a stop below the 50-d…
Vermilion Energy is trading above its key moving averages, carrying momentum after a strong Q2 reaction. With a $1.675B market cap, a 3.3% yield, and a history of asset rationalization to cut debt, VET looks like an actionable mid‑term long. Entry at $11.00, stop at $10.00, target $13.50 over ~45 trading days.
Envista (NVST) delivered an upside quarter and raised guidance, and the shares trade at reasonable enterprise multiples given cash flow generation and exposure to growing dental equipment and clear-aligner markets. This trade idea lays out a tactical long: entry at $27.00, stop $24.50, target $34.00 (180 trading days).
Chemours (CC) sold off after a clear Q2 reset on 08/05/2026. That pullback creates a tactical entry near $15.10 where the market has largely priced in temporary headwinds (channel destocking, lost SPS contribution). With free cash flow of $154M, a $2.27B market cap, attractive end-market exposure to low-GWP blowing agents and AI cooling materials, …
Hercules Capital (HTGC) screens as one of the more attractive BDC opportunities right now: market cap near $3.22B, a 9.5% dividend yield, portfolio metrics that point to minimal realized credit stress (0.1% non-accruals, 125% coverage), and a share price still below last summer's highs. Pair that with improving technical momentum and compressed val…
BrightSpring is reshaping into a higher-margin, cash-generative provider of home- and community-based health services after divestitures and operational progress. Revenue and adjusted EBITDA growth, a meaningful free cash flow stream ($402.4M) and a $14.13B enterprise value that still prices growth make BTSG a constructive pick for a position trade…
MPLX remains a top-tier midstream operator with a durable 7%-plus yield, strong free cash flow and attractive coverage. The trade here is to own exposure for income while protecting capital: enter around current levels, set a tight stop, and target a breakout above the 52-week high for upside. I like owning MPLX for distributions, but I have stoppe…
